Generation Bio Co. is a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases. The company is developing distinct and complementary platforms a potent, highly selective cell-targeted lipid nanoparticle delivery system and a novel immune-quiet DNA cargo produced by a scalable capsid-free manufacturing process which uses proprietary cell-free rapid enzymatic synthesis. Generation Bio Co. is based in CAMBRIDGE, Mass.
Revenue (Most Recent Fiscal Year) | $19.89M |
Net Income (Most Recent Fiscal Year) | $-131.67M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 1.88 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.74 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -341.12% |
Net Margin (Trailing 12 Months) | -341.12% |
Return on Equity (Trailing 12 Months) | -91.07% |
Return on Assets (Trailing 12 Months) | -33.65% |
Current Ratio (Most Recent Fiscal Quarter) | 7.51 |
Quick Ratio (Most Recent Fiscal Quarter) | 7.51 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $12.91 |
Earnings per Share (Most Recent Fiscal Quarter) | $-3.12 |
Earnings per Share (Most Recent Fiscal Year) | $-19.80 |
Diluted Earnings per Share (Trailing 12 Months) | $-10.82 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 6.74M |
Free Float | 5.27M |
Market Capitalization | $39.94M |
Average Volume (Last 20 Days) | 0.08M |
Beta (Past 60 Months) | 2.48 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 21.80% |
Percentage Held By Institutions (Latest 13F Reports) | 95.22% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |